Literature DB >> 32270331

Endocan as a predictor of increased cardiovascular risk during the menopausal transition period.

Şükrü Yıldız1, Cihan Kaya2, Asuman Gedikbaşı3, Hüseyin Cengiz4, İsmail Alay2, Emine Öztürk2, Aysun Fendal Tunca2, Levent Yaşar2.   

Abstract

PURPOSE: Our aim was to investigate the serum endocan levels and carotid artery intima-media thickness (CIMT) measurements of pre- and postmenopausal patients to clarify the relationship between the menopausal transition and endothelial injury.
METHODS: This cross-sectional study was conducted on women who were premenopausal and postmenopausal between January 2019 and June 2019. The patients were divided into two groups according to premenopausal (n = 32) and postmenopausal (n = 32) status. Serum endocan levels were assessed by enzyme-linked immunosorbent assay (ELISA). CIMT ultrasonographic measurements were determined. Hormonal and biochemical parameters were measured. The validated Menopause Rating Scale (MRS) questionnaire was used on all women.
RESULTS: Serum endocan levels were significantly higher in the postmenopausal group than in the premenopausal group (222.90 ± 121.00 ng/L and 146.62 ± 41.88 ng/L, p = 0.033, respectively). The mean CIMT was significantly higher in the postmenopausal group than in the premenopausal cohort (0.70 ± 0.14 mm and 0.58 ± 0.11 mm, p < 0.001, respectively). A positive correlation was found between body mass index (BMI), systolic blood pressure (SBP), abdominal circumference (AC), and CIMT and postmenopausal serum endocan levels. Serum endocan levels with a cutoff point of 141.14 ng/L identified women with significant CIMT levels with sensitivity of 73.8% and specificity of 77.3%. A positive correlation was found between CIMT and endocan and total MRS scores.
CONCLUSION: Serum endocan levels were associated with CIMT during the menopausal transition period. Increased circulating endocan levels can be a predictor of cardiovascular risk in pre- and postmenopausal women.

Entities:  

Keywords:  Biomarker; Endocan; Endothelial dysfunction; Menopause

Mesh:

Substances:

Year:  2020        PMID: 32270331     DOI: 10.1007/s00404-020-05520-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  [Normal value correlates of carotid intima- media thickness and affecting parameters in healthy adults].

Authors:  Fahri Halit Beşir; Sibel Yazgan; Gökhan Celbek; Mesut Aydın; Omer Yazgan; Melih Engin Erkan; Mesut Erbaş; Adem Güngör
Journal:  Anadolu Kardiyol Derg       Date:  2012-05-16

2.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2009-12-17       Impact factor: 29.690

3.  Endocan elicits severe vascular inflammatory responses in vitro and in vivo.

Authors:  Wonhwa Lee; Sae-Kwang Ku; Shin-Woo Kim; Jong-Sup Bae
Journal:  J Cell Physiol       Date:  2014-05       Impact factor: 6.384

4.  Obesity and reproductive hormone levels in the transition to menopause.

Authors:  Ellen W Freeman; Mary D Sammel; Hui Lin; Clarisa R Gracia
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 5.  Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.

Authors:  S Sarrazin; E Adam; M Lyon; F Depontieu; V Motte; C Landolfi; H Lortat-Jacob; D Bechard; P Lassalle; M Delehedde
Journal:  Biochim Biophys Acta       Date:  2005-08-26

6.  Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome.

Authors:  Merve Bicer; Aslı Guler; Gokcen Unal Kocabas; Cetin Imamoglu; Ali Baloglu; Oktay Bilgir; Arif Yuksel; Giray Bozkaya; Mehmet Calan
Journal:  Endocr Res       Date:  2016-12-02       Impact factor: 1.720

Review 7.  Endocan: A novel inflammatory indicator in cardiovascular disease?

Authors:  Sevket Balta; Dimitri P Mikhailidis; Sait Demirkol; Cengiz Ozturk; Turgay Celik; Atila Iyisoy
Journal:  Atherosclerosis       Date:  2015-09-26       Impact factor: 5.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.